Alport Syndrome - Epidemiology Forecast - 2036

Alport Syndrome Insights and Trends

• Alport syndrome is a rare inherited kidney disorder caused by mutations in type IV collagen genes (COL4A3, COL4A4, COL4A5), leading to structural abnormalities of the glomerular basement membrane and characterized by progressive renal impairment, sensorineural hearing loss, and eye abnormalities.
• It is a lifelong condition with an estimated prevalence of ~1 in 5,000-10,000 individuals, though the true burden is likely underestimated due to underdiagnosis and recognition of a broader "Alport spectrum", encompassing both severe and milder phenotypes.
• Individuals with Alport syndrome may experience symptoms for an extended period before receiving a diagnosis. The condition is frequently without symptoms until later stages, and having a family history of Alport syndrome serves as a crucial signal for undergoing screening.
• Diagnosis remains challenging and is frequently delayed due to phenotypic variability and overlap with other renal conditions (e.g., IgA nephropathy), with genetic testing now considered the gold standard but still not universally implemented in routine clinical practice.
• The underlying pathophysiology involves defective type IV collagen assembly, resulting in progressive glomerular basement membrane thinning, splitting, and fibrosis, ultimately driving chronic kidney disease progression and systemic manifestations.

Alport syndrome Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Alport Syndrome: ~29,500
• Alport Syndrome Growth Rate (2026-2036): ~0.5% CAGR

DelveInsight's 'Alport Syndrome - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the alport syndrome, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Alport Syndrome Understanding and Diagnostic Algorithm

Alport Syndrome Overview and Diagnosis

Alport syndrome is a hereditary disorder caused by mutations in type IV collagen genes (COL4A3, COL4A4, COL4A5), affecting basement membranes of the kidneys, ears, and eyes. It presents with early hematuria and progressive kidney dysfunction that can lead to renal failure, often accompanied by hearing loss and ocular abnormalities. The disease occurs in X-linked, autosomal recessive, and autosomal dominant forms, with X-linked being the most common and severe in males. Diagnosis relies on clinical features, family history, biopsy findings, and increasingly genetic testing. There is no curative treatment; management focuses on slowing disease progression using supportive therapies, though many patients eventually require dialysis or kidney transplantation.

The diagnostic approach to Alport syndrome integrates clinical suspicion, laboratory testing, and advanced genetic analysis. It is typically suspected in individuals with persistent hematuria, family history of kidney disease, early hearing loss, or unexplained renal impairment. Initial evaluation includes urine and blood tests to assess hematuria, proteinuria, and kidney function, though these findings are not disease-specific. Kidney biopsy can provide supportive evidence through structural and collagen abnormalities, while skin biopsy may aid in select cases. However, genetic testing has become the gold standard, enabling definitive identification of mutations in COL4A3, COL4A4, and COL4A5 genes and determination of inheritance patterns. Complementary assessments such as audiometry and ophthalmologic evaluation further support diagnosis and disease monitoring.

Alport Syndrome Epidemiology

Key Findings from Alport Syndrome Epidemiological Analysis and Forecast

• Alport syndrome is caused by mutations in the genes responsible for alpha-3, alpha-4, and alpha-5 chains of type IV collagen. The prevalence of Alport syndrome is not well-documented but is believed to be found in about 1 in every 50,000 live births worldwide.
• The total diagnosed prevalent cases of Alport syndrome in the 7MM were 29,500 cases in 2025 and are projected to rise by 2036.
• In 2025, EU4 and the UK accounted for 7,000 cases in males and 6,400 cases in females. These cases are expected to increase to 9,441 cases and 8,715 cases in males and females, respectively by 2036.
• In 2025, the 18 years and above age segment accounted for the highest number of cases in EU4 and the UK i.e, 11,400 cases whereas, the 12-17 years age segment had the least number of cases accounting for 870 cases. These cases are expected to increase by 2036.

Scope of the Report:

• The report covers a segment of an executive summary, a descriptive overview of Alport syndrome, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• Alport syndrome Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of alport syndrome? What will be the growth opportunities across the 7MM concerning the patient population with alport syndrome?
• What is the historical and forecasted alport syndrome patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.